Clinical trials: Hepatitis C, completed
Non-alcoholic Steato-hepatitis
: Identification of Non-alcoholic Steato-hepatitis Cases in a Sample of Type 2 Diabetes Patients, with a Disruption of the Liver Function Tests, At the Pointe-à-Pitre University Hospital
Non-alcoholic steatohepatitis (NASH) develops on insulin resistance, especially in patients with carbohydrate tolerance. NASH may progress to more extensive fibrosis, including cirrhosis, but also to HCC with or without cirrhosis…
- Trial name
- STEATOGWAD (NCT06738810)
- Testing
- Fibrotest-actitest/NASHtest
- Where
- Guadeloupe
- Volunteers
- 103 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Influenza, Hepatitis A
Effects of Aging on Primary and Secondary Vaccine Responses
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (>65 years) subjects whose yearly influenza vaccine responses have been studied extensively…
- Conditions
- Influenza, Hepatitis A, Typhoid, Healthy Adults
- Trial name
- SLVP033 (NCT03312699)
- Testing
- Fluzone® quadrivalent, Fluzone High Dose, Fluad
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Stanford University
Leptospirosis, Hepatitis E Virus Infection
Seroprevalence of Leptospirosis in Val Müstair, Switzerland
Human leptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. Due to its frequent inapparent course or mild severity with unspecific symptoms and limited availability of diagnostic laboratories the…
- Conditions
- Leptospirosis, Hepatitis E Virus Infection, Tularemia
- Trial name
- NCT05300425
- Testing
- Blood sample collection, Data collection
- Where
- 2 sites in Switzerland
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
HIV, Hepatitis C
Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)
This study will evaluate the referral to harm reduction services (HRS) including syringe services, naloxone overdose prevention, substance use treatment referral, HIV, HCV, and STD testing and referral and linkage to care through…
- Conditions
- HIV, Hepatitis C, Opioid-use Disorder, Injection Drug Use
- Trial name
- ETHIC (NCT04427202)
- Testing
- Referral to harm reduction services
- Where
- 2 sites in United States
- Volunteers
- 306 people
- Sponsor
- University of Chicago
HIV Infections, Hepatitis C
Tajik Migrant Health Education Study
This study will test the efficacy of a peer-education prevention intervention to reduce risky drug, alcohol, and sexual behaviors among male Tajik labor migrants who inject drugs (MWID) while working in Moscow.
- Conditions
- HIV Infections, Hepatitis C, Risky Health Behavior, Risk Reduction Behavior
- Trial name
- NCT04853394
- Testing
- MASLIHAT, TANSIHAT
- Where
- Russia
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Chronic Hepatitis B
A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection
This is a randomized, double-blind, placebo-controlled, single (Part A) and repeated dose (Part B) escalation, phase I clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) of RBD1016…
- Trial name
- NCT05017116
- Testing
- RBD1016, Entecavir
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Suzhou Ribo Life Science Co. Ltd.
Measurement of Immune Response to Prevenar13, Measurement of Immune Response to Hepatitis A
PCV13 + Hepatitis A Vaccine for Adults
The present study explores whether a simultaneously given hepatitis A vaccine (Epaxal) will have an impact on the immune response to PCV13 (pneumococcal conjugate vaccine; Prevenar13) vaccine in adults.
- Trial name
- PCV13+HepA (NCT01926860)
- Testing
- Prevenar13, Hepatitis A vaccine
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
HAV
Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23)
The purpose of this study is to evaluate the clinical performance supporting that intended purpose of the Access anti-HAV as an aid in the laboratory diagnosis of HAV infection and for detection of anti-HAV after vaccination and…
- Trial name
- NCT06289868
- Testing
- Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays, Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
- Where
- 2 sites in France
- Volunteers
- 1,409 people
- Sponsor
- Beckman Coulter, Inc.
Chronic Hepatitis C
Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin
•The purpose of this study is to compare the performance between liver biopsy and non-invasive fibrosis assessments evaluating anti-fibrotic efficacy of peginterferon plus ribavirin in patients with hepatitis C pre- and…
- Trial name
- NCT01634919
- Testing
- chronic hepatitis C
- Where
- 2 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Seoul National University Boramae Hospital
Chronic Hepatitis B
A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).
- Trial name
- NCT05905458
- Testing
- HRS9950 tablets
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Chronic Hepatitis b
A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
The objective of this study is to evaluate the safety and efficacy of ASC22 in the treatment of chronic hepatitis B after single and multiple drug administration.
- Trial name
- NCT04465890
- Testing
- ASC22, sodium chloride
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference
This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04389593
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Cirrhosis, Hepatitis B Infection
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment…
- Conditions
- Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT02143401
- Testing
- Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study
- Where
- 10 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis B, Cirrhosis
Prevention of Recurrent Hepatitis B After Liver Transplantation
Hepatitis B accounts for approximately 5000 deaths per year in the United States. Liver transplantation offers the only hope for patients who develop end-stage liver disease.
- Conditions
- Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT00059267
- Testing
- HBIG, Epivir, Hepsera
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis b
Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects
The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and food effect of HRS9950.
- Trial name
- NCT04464733
- Testing
- HRS9950
- Where
- China
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatitis B, Chronic
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants
This study is a multicenter, three-part study. Parts 1 and 2 are randomized, investigator- and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety…
- Trial name
- NCT02952924
- Testing
- Midazolam, RO7049389
- Where
- 21 sites in Australia, Bulgaria and 6 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis B
A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects
This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects.
- Trial name
- NCT06160895
- Testing
- TQ-A3334 tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hypoxic-Ischemic Encephalopathy, Hepatitis B Vaccination
Hypothermia's Effect on Hepatitis B Vaccination
The purpose of the research is to determine if the Hepatitis B vaccine after birth provides enough protection after cooling for Hypoxic Ischemic Encephalopathy (HIE).
- Conditions
- Hypoxic-Ischemic Encephalopathy, Hepatitis B Vaccination, Hypothermia, Newborn
- Trial name
- NCT05787899
- Testing
- Hypothermia Protocol
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical University of South Carolina
Hepatitis B, Chronic
Linkage to Care and Treatment of Chronic HBV Patients
Chronic hepatitis B remains the leading cause of liver related mortality and morbidity globally and locally. Countries have been formulating initiatives to meet the WHO target of eliminating viral hepatitis by 2030.
- Trial name
- HBV (NCT06658678)
- Testing
- Receiving an educational intervention
- Where
- Hong Kong
- Volunteers
- 803 people
- Sponsor
- The University of Hong Kong
Hepatitis B
Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients
This study is a multi-center, double-blind, active-controlled, randomized, parallel clinical study to evaluate the efficacy and safety of DA-2803 in chronic hepatitis B subjects
- Trial name
- NCT05957380
- Testing
- DA-2803, DA-2803-R
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Dong-A ST Co., Ltd.